Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2026 | G-DISCO: synchronous gemcitabine and docetaxel as an intravesical therapy for high-risk NMIBC

Dickon Hayne • 15 Mar 2026
EAU 2026
Bladder Cancer Genitourinary Cancer Docetaxel Gemcitabine
G-DISCO

Dickon Hayne, MBBS, MD, FRCS, FRACS, UWA Medical School, Perth, Australia, discusses the G-DISCO trial, a first-in-human phase one study that investigated the use of synchronous gemcitabine and docetaxel as an intravesical therapy for high-risk non-muscle invasive bladder cancer (NMIBC), which showed promising results with over 60% three-month disease-free survival and 81% high-grade recurrence-free survival. Dr Hayne highlights that this approach may offer a significant change in treatment, potentially being more efficacious, cost-saving, and safer than administering the drugs sequentially. This interview took place at the 41st Annual EAU Congress in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Dickon Hayne

CAIX expression in urothelial cancer
0:46
CAIX expression in urothelial cancer
Dickon Hayne • 13 Mar 2026
ANZUP 1301: effects on urinary symptoms and other aspects of HRQL
2:38
ANZUP 1301: effects on urinary symptoms and other aspects of HRQL
Dickon Hayne • 15 Mar 2026
ZiPUP: 89Zirconium-labelled girentuximab PET in patients with urothelial cancer
4:43
ZiPUP: 89Zirconium-labelled girentuximab PET in patients with urothelial cancer
Dickon Hayne • 13 Mar 2026
ANZUP 1301: BCG + mitomycin a promising alternative to BCG alone for high-risk bladder cancer
1:03
ANZUP 1301: BCG + mitomycin a promising alternative to BCG alone for high-risk bladder cancer
Dickon Hayne • 31 May 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals